You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍隨大市造好 來凱、開拓及百心安漲逾9%-25%
恆指午後高見17,788,現報17,773,回升319點或1.8%,總成交額720億元。 醫藥板塊今天普遍跟隨大市,尤其是百心安-B(02185.HK)高見4.58元,現報4.43元,急漲25.5%。 開拓藥業-B(9939.HK)高低見3.49元/3.92元,現報3.39元,續漲15%,成交續增至1,680萬股。 今年6月才以每股12.41元上市的來凱醫藥-B(02105.HK)連升第二天,高見25.4元,暫受制本月初所創上市高位26.45元,現報24.7元,升9.1%。 藥明系全線升1%-5%,藥明巨諾(02126.HK)扭兩連跌,現報2.64元(剛為10天線),回升5.6%;將於12月4日正式「染藍」藥明康德(02359.HK)扭兩連跌,高見97.25元,現報96.85元,回升4%;藍籌藥明生物(02269.HK)反覆回升1.4%報47.9元;上周五掛牌的藥明合聯(02268.HK)繼首日急漲36%後,今天反覆探頂,高低見29.4元/27.2元,現報28.65元,續升2.3%。 藍籌石藥(01093.HK)、艾美疫苗(006660.HK)、神威藥業(02877.HK)、君實(01877.HK)、再鼎醫藥(09688.HK)、四環藥業(00460.HK)、騰盛博藥-B(02137.HK)及諾誠健華(09969.HK)升逾2%-3%。 然而,屢尋底康寧傑瑞製藥-B(09966.HK)、百濟神州(06160.HK)、康方生物(09926.HK)及信達生物(01801.HK)反覆受壓,後兩者現報46.1元及43.9元,反覆回吐1.5%及1.7%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account